Search

Your search keyword '"Takahashi, Koichi"' showing total 3,293 results

Search Constraints

Start Over You searched for: Author "Takahashi, Koichi" Remove constraint Author: "Takahashi, Koichi"
3,293 results on '"Takahashi, Koichi"'

Search Results

1. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

6. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

9. The Future of Fundamental Science Led by Generative Closed-Loop Artificial Intelligence

10. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

11. LLMs can generate robotic scripts from goal-oriented instructions in biological laboratory automation

12. Distinct landscape and clinical implications of therapy-related clonal hematopoiesis

13. Scenarios and branch points to future machine intelligence

14. Segmentation-free Direct Iris Localization Networks

16. Optical dispersions through intracellular inhomogeneities

19. Polarization of the Corona Observed During the 2017 and 2019 Total Solar Eclipses

20. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

21. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

23. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

24. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

25. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

26. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells

27. Signaling activations through G-protein-coupled-receptor aggregations

28. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

31. SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation

32. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results

35. Cooperativity transitions driven by higher-order oligomer formations in ligand-induced receptor dimerization

36. Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

37. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

41. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

45. Surface reaction-diffusion kinetics on lattice at the microscopic scale

46. Reaction-diffusion kinetics on lattice at the microscopic scale

47. Solar Coronal Jets Extending to High Altitudes Observed During the 2017 August 21 Total Eclipse

48. Simulation of live-cell imaging system reveals hidden uncertainties in cooperative binding measurements

49. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

50. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Catalog

Books, media, physical & digital resources